This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Stock Market News for Feb 6, 2025
by Zacks Equity Research
U.S. stock markets closed higher on Wednesday posting back-to-back closing in green.
GRALNegative Net Change
biotechnology
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
REGNPositive Net Change BIIBNegative Net Change AMGNPositive Net Change AXSMNegative Net Change VRTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Q4 Earnings Beat Estimates, GLP-1 Drugs Boost Sales, Stock Up
by Zacks Equity Research
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes and Obesity care products.
ALNYPositive Net Change NVOPositive Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy Pacira (PCRX) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PCRXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Zacks.com featured highlights BioMarin, Cheesecake Factory, Leidos and The Ensign
by Zacks Equity Research
BioMarin, Cheesecake Factory, Leidos and The Ensign have been highlighted in this Screen of The Week article.
BMRNNegative Net Change CAKENegative Net Change LDOSNegative Net Change ENSGNegative Net Change
biotechnology
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
by Zacks Equity Research
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
REGNPositive Net Change SNYPositive Net Change RHHBYPositive Net Change BAYRYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS
by Zacks Equity Research
Pfizer's late-stage BRAF V600E-mutant mCRC study of the Braftovi combo regimen meets its other dual primary endpoint of PFS with statistical significance.
ALNYPositive Net Change PFENegative Net Change LLYPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Company News for Feb 4, 2025
by Zacks Equity Research
Companies In The News Are: ARLP, TSN, IDXX, TWST.
TSNNegative Net Change IDXXNegative Net Change ARLPPositive Net Change TWSTPositive Net Change
biotechnology consumer-staples medical oil-energy
BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi
by Zacks Equity Research
The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma and Breyanzi for relapsed or refractory follicular lymphoma.
ALNYPositive Net Change BMYNegative Net Change BMRNNegative Net Change EXELNegative Net Change
biotechnology biotechs pharmaceuticals
Should Bristol Myers Stock Be in Your Portfolio Pre-Q4 Earnings?
by Ekta Bagri
BMY is looking to turn its business around, banking on the strong uptake of new drugs. The recent spate of positive regulatory updates also bodes well for the stock. We recommend investors to wait for better entry levels.
BMYNegative Net Change PFENegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock?
by Ahan Chakraborty
NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs earnings-preview medical pharmaceuticals
Biogen Stock Down on Regulatory Update in the EU for Alzheimer's Drug
by Zacks Equity Research
The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.
BIIBNegative Net Change LLYPositive Net Change PRTAPositive Net Change CSTLPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis Posts Q4 Earnings and Sales Beat, Shares Gain
by Zacks Equity Research
NVS' fourth-quarter earnings and sales beat estimates. Based on the strong momentum of the company???s key drugs, it provides an encouraging outlook for 2025.
ALNYPositive Net Change NVSPositive Net Change RHHBYPositive Net Change BMRNNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
by Zacks Equity Research
CMPX stock more than doubles following updates regarding the pipeline development programs and current cash position by the company.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change CMPXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
by Zacks Equity Research
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
by Zacks Equity Research
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
REGNPositive Net Change RHHBYPositive Net Change PRTAPositive Net Change
biotechnology biotechs medical pharmaceuticals
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Teva stock falls 14% despite better-than-expected fourth-quarter earnings results due to a weak 2025 outlook.
SNYPositive Net Change JNJPositive Net Change TEVAPositive Net Change ABBVPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics
by Zacks Equity Research
Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics are part of the Zacks top Analyst Blog.
BIIBNegative Net Change CYTKPositive Net Change AKROPositive Net Change
biotechnology biotechs
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
by Zacks Equity Research
SAGE and AKRO are up this week on regulatory and pipeline updates.
BIIBNegative Net Change CYTKPositive Net Change AKROPositive Net Change
biotechnology biotechs medical pharmaceuticals
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study
by Zacks Equity Research
Akero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead product candidate, EFX.
NVOPositive Net Change MDGLNegative Net Change AKROPositive Net Change ETNBNegative Net Change
biotechnology biotechs medical pharmaceuticals
How to Play NVO Stock After New Drug's Success in Obesity Study
by Ahan Chakraborty
The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh in on the stock's growth prospects.
NVOPositive Net Change LLYPositive Net Change AMGNPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
by Zacks Equity Research
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
AZNPositive Net Change ALNYPositive Net Change BMRNNegative Net Change CSTLPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Grupo Aeroportuario del Centro Norte (OMAB)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
OMABNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
UiPath (PATH) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
PATHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform
by Zacks Equity Research
EXEL loses 5% after Oppenheimer downgrades its rating to Perform from Outperform on concerns about the potential differentiation of pipeline candidate zanzalintinib versus cabozantinib following the abstract for STELLAR-001 study.
BMYNegative Net Change MRKPositive Net Change EXELNegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals